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A B S T R A C T
Accumulating evidence suggests that natural bioactive compounds, alone or in combination with traditional
chemotherapeutic agents, could be used as potential therapies to ﬁght cancer. In this study, we employed four
natural bioactive compounds (curcumin, resveratrol, melatonin, and silibinin) and studied their role in redox
control and ability to promote apoptosis in androgen sensitive and insensitive prostate cancer cells. Here is
shown that curcumin and resveratrol promote ROS production and induce apoptosis in LNCaP and PC-3. An
increase in reactive species is a trigger event in curcumin-induced apoptosis and a consequence of resveratrol
eﬀects on other pathways within these cells. Moreover, here we demonstrated that these four compounds aﬀect
diﬀerently one of the main intracellular redox regulator, the thioredoxin system. Exposure to curcumin and
resveratrol promoted TRX1 oxidation and altered its subcellular location. Furthermore, resveratrol diminished
TRX1 levels in PC-3 cells and increased the expression of its inhibitor TXNIP. Conversly, melatonin and silibinin
only worked as cytostatic agents, reducing ROS levels and showing preventive eﬀects against TRX oxidation. All
together, this work explores the eﬀect of compounds currently tested as chemo-preventive agents in prostate
cancer therapy, on the TRX1 redox state and function. Our work shows the importance that the TRX system
might have within the diﬀerences found in their mechanisms of action. These bioactive compounds trigger
diﬀerent responses and aﬀect ROS production and redox systems in prostate cancer cells, suggesting the key role
that redox-related pathways might play in processes like diﬀerentiation or survival in prostate cancer.
1. Introduction
Reactive oxygen species (ROS) are generated in response to
endogenous and exogenous stimuli. Under physiological conditions,
basal low levels of ROS are crucial mediators of multiple cell processes
including growth, migration or diﬀerentiation. However, an excess of
ROS production induces the so called oxidative stress, causing oxidative
damage to macromolecules and thus leading to cell death, apoptosis
and/or senescence. As a consequence, oxidative stress has been related
to the pathogenesis of various diseases including cancer, diabetes and
neurodegenerative diseases [1,2]. Many studies suggest that cancer
cells show increased oxidative stress associated with alterations in
metabolic activity and oncogenic transformation. Higher ROS produc-
tion plays an important role in tumor initiation and progression [3].
However, oxidative stress also renders cancer cells vulnerable to be
damaged by further ROS production induced by exogenous agents.
Therefore, manipulating ROS levels by redox modulation become an
eﬀective therapeutic approach to selectively kill cancer cells without
causing signiﬁcant toxicity to normal cells [4,5].
Physiologically generated ROS are controlled by non-enzymatic and
enzymatic anti-oxidants, such as superoxide dismutases, catalase,
peroxiredoxins and glutathione peroxidases. The thioredoxin (TRX)
system composed of TRX, thioredoxin reductase (TRXR), and NADPH, is
one of the main thiol-dependent electron donors systems in the cell. It
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plays a critical role in the regulation of cellular redox environment and
in a wide range of signaling pathways [6–8]. TRX acts as an
intermediate that senses cellular redox state and transmits information
to signaling molecules such as apoptosis signal-regulating kinase 1
(ASK1) [9]. ASK1 is a member of the mitogen-activated protein kinase
(MAP3K) family that is involved in apoptosis and diﬀerentiation [10].
Reduced TRX negatively regulates ASK1 preventing apoptosis by
binding to its N-terminal domain [9,11].
Prostate cancer (PCa) is one of the most common malignancies and
the second leading cause of cancer-related male mortality in western
countries [12]. PCa growth is initially androgen-dependent and thus
androgen ablation is the standard therapeutic option. Nevertheless,
malignant prostate tumors eventually relapse after treatment, becoming
hormone-independent and resistant to conventional therapies.
Several bioactive compounds derived from natural sources have
been at the forefront research of new therapies against PCa [13]. First,
epidemiologic data suggested that some diet habits are related to a
lower incidence of certain tumors types. Then, preclinical studies using
cells or animal models supported the role of some bioactive compounds
as chemo-preventive agents. Their relatively low toxicity, low cost, easy
availability and their possible role as adjuvants that potentiate the
eﬀect of diﬀerent chemotherapeutic drugs has been investigated for the
last years [14–17]. In the current study, the eﬀect of four natural
compounds, i.e.: curcumin, a natural dye extracted from Curcuma longa
L.; resveratrol, a polyphenolic stilbene found in grapes; silibinin, a
naturally-occurring ﬂavonoid produced by milk thistle and melatonin,
an indole that is mainly produced by the pineal gland in vertebrates but
also found in edible plants [18], was investigated. All of them have
shown eﬀects against tumor growth in cells or in rodent models of
prostate cancer [19–21], though, the molecular pathways involved in
their mechanisms of action, in particular the redox signaling pathways
altered, still remain unclear. In this study, we aim to investigate ROS-
mediated apoptosis signaling pathways induced by these bioactive
compounds that have displayed antioxidant or pro-oxidant activities
in vitro [22–25]. Since TRX1 has been proposed as a subcellular
biomarker of redox imbalance in human prostate cancer progression
[26], its role in androgen-dependent and independent prostate cancer
cells apoptosis caused by these bioactive compounds was evaluated.
2. Material and methods
2.1. Cell culture and drugs treatments
Human androgen-dependent epithelial prostate cancer cells
(LNCaP) were purchased from European Collection of Cell Cultures
(Catalog number 89110211, Salisbury, UK) and were cultured in
RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine,
15 mM HEPES, 100 µg/ml ampicillin and 100 µg/ml kanamycin. PC-
3 cells, a human prostate androgen-independent adenocarcinoma
cell line, purchased from American Type Culture Collection (Catalog
number CRL-1435, Manassas, VA, USA) were grown in DMEM/F12
medium supplemented with 10% FBS, 2% L-glutamine and 1%
antibiotic-antimycotic cocktail (100 U/ml penicillin, 10 µg/ml strep-
tomycin and 0.25 µg/ml amphotericin B). Both cell lines were grown
at 37 °C in a humidiﬁed 5% CO2 environment. The medium was
changed every 2 days and cultures were split at least once a week,
when they reached 80% conﬂuence. IC50 concentration of each
compound based on cell viability and proliferation assays was
employed. Thus, in the following studies 1 mM melatonin, 50 µM
silibinin, 25 µM curcumin and 50 µM resveratrol were chosen.
Natural compounds were added directly in complete culture medium
from a stock solution using dimethyl sulfoxide (DMSO, Sigma-
Aldrich) as a vehicle. DMSO was added to each control and
experimental group.
2.2. Cell viability
Cell viability was evaluated by MTT reduction assay (BQCell™ MTT,
Bioquochem, Oviedo, Spain). Cells were seeded in 96 well plates and
then treated with several concentrations of each compound for 48 h.
Base on previous reports, concentrations range for each compound were
chosen as follow, curcumin (1.6–25 µM), resveratrol (6.12–100 µM),
melatonin (0.062–1 mM) and silibinin (6.12–100 µM). After treatment,
MTT was added to each well. Four hours later, cells were lysed by
adding one volume of lysis buﬀer and left overnight at 37 °C.
Absorbance at 570 nm was measured using a microplate reader (Cary
50-MPR; Agilent Technologies, Santa Clara, CA, USA). Experiments
were repeated at least three times. Results are shown as the media of six
samples± SEM.
2.3. Apoptosis. Annexin V staining
Apoptosis was evaluated by annexin V/propidium iodide staining by
using Annexin V-FITC Apoptosis Detection Kit (BD Biosciences, 2350
Qume Drive, San Jose, California, USA) following manufacturer´s
instructions. Fluorescence was analyzed by using a Becton-Dickinson
Immunocytometry Systems FACStar Plus ﬂow cytometer, equipped
with an argon-ion laser. At least 104 cells were analyzed in each
experimental group.
2.4. Cell cycle analysis
Cell cycle distribution was determined by ﬂow cytometry
(Becton–Dickinson and Beckman– Coulter). After 48 h incubation with
compounds, cells were harvested and ﬁxed in 70% ethanol at 4 °C for
24 h. Then, cells were incubated with RNaseA (100 mg/l) at 37 °C for
30 min and stained with propidium iodide (10 mg/l) (Sigma-Aldrich).
Samples were analyzed for DNA content using a Coulter EPICS-XL
Cytometer.
2.5. Detection of intracellular and mitochondrial ROS levels
MitoSOX red (Invitrogen, Carlsbad, CA, USA), Dihydroethidium
(DHE, Sigma-Aldrich), and 2′-7′-dichlorodihydroﬂuorescein diacetate
(DCFH2-DA, Sigma-Aldrich) staining were employed to detect intra-
mitochondrial or intracellular O2•- levels and general ROS production,
respectively. For MitoSOX and DHE staining, cells were treated with
each bioactive compound for 30 min and for H2-DCFDA, cells were
treated for 3, 6 or 24 h. Cells were collected by trypsinization and
resuspended in 1 ml of PBS plus glucose (1 g/l glucose) and 0.1% FBS
containing 1 μM MitoSOX, 2 µM DHE or 1 μM DCFH2-DA. Cells were
then incubated with MitoSOX for 10 min and with DHE and DCFH2-DA
for 30 min at 37 °C. Stained cells were analyzed by ﬂow cytometry
(Beckman-Coulter EPICS-XL Cytometer). Data analysis was performed
using Kaluza Analysis Software (Beckman-Coulter).
2.6. Hydrogen peroxide determination
Hydrogen peroxide (H2O2) was electrochemically assayed as pre-
viously reported [27] using screen-printed electrodes (Bioquochem SL,
Oviedo, Spain). Brieﬂy, cells were cultured in complete medium at a
density of 75×105 cells/ml and incubated with compounds for 24 h.
Samples of the medium were collected and a small aliquot of 30 µl of
cell-free culture medium was placed on the electrode surface. Intensity
(µA) was registered for 200 s employing +0.4 V as working potential.
To determine H2O2, each sample was measured before and 5 min after
adding catalase to blank sample. Measurements were done using an e-
BQC portable device.
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2.7. Transient transfections
Two of the natural compounds employed in this study seemed to
induce diﬀerentiation in prostate cancer cells while the others induced
apoptosis. Thus, the possible role of the MAP kinase ASK1, which has
been linked to both processes, within these diﬀerences was investi-
gated. Cells were transiently transfected with hASK1-HA-pcDNA3 or the
catalytically inactive form hASK1-KM-HApcDNA3. Plasmids were a gift
from Dr. Hidenori Ichijo (University of Tokyo). LNCaP and PC-3 cells
were plated at a density of 5×104 cells/ml in 24-well cell culture
dishes. After 48 h cells were transfected with 1.0 μg of plasmid DNA
using Lipofectamine (Invitrogen) following the manufacturer's instruc-
tions.
2.8. SDS-PAGE and immunoblotting
Cells were seeded in 100 mm dishes and allowed to attach over-
night. After treatment for 48 h, cells were washed with ice cold
phosphate buﬀered saline (PBS) and lysed in RIPA lysis buﬀer
(50 mM Tris–HCl, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS),
1% Igepal C, 0.5% sodium deoxycholate, 1 mM Dithiothreitol (DTT),
and protease inhibitors (10 μg/ml leupeptin, 2 μg/ml aprotinin, 1 μg/
ml pepstatin, 200 μM sodium orthovanadate and 1 mM phenylmethyl-
sulfonyl ﬂuoride (PMSF)) (Sigma-Aldrich). Fifty micrograms of protein
were loaded in 12–15% SDS polyacrylamide gels and electrotransferred
to PVDF membranes. The following antibodies were employed: anti-
CuZnSOD (Calbiochem, MerckChemicals Ltd, Nottingham, UK), anti-
catalase, anti-Bcl-2 (Calbiochem), anti-Bax, anti-Trx1, anti-GAPDH and
anti-β actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Immunoreactivity was detected by using enhanced Immobilon
Western Substrates ECL (Millipore).
2.9. Nuclear and cytosolic fractionation
Cells were seeded in 100 mm dishes at a density of 5×104 cells/ml
and allowed to attach overnight. After 48 h treatment, cells were
washed with ice-cold PBS and nuclear and cytosolic proteins were
extracted after harvesting cells by scrapping. Cells were lysed in ice-
cold Buﬀer A (10 mM HEPES, pH 7.9, 15 mM KCl, 2 mM MgCl2, 1 mM
DTT, Sigma-Aldrich) and 0.1 mM EDTA) supplemented with protease
inhibitors (1 mM PMSF, 1g/ml aprotinin, 0.3g/ml leupeptin) and 0.2%
Igepal C (Sigma-Aldrich). Nuclear fractions were collected by centrifu-
gation at 14,000×g 5 min at 4 °C and supernatants (cytosolic fraction)
were transferred to clean tubes. Nuclei were resuspended in 20 µl of
Buﬀer B (250 mM Tris–HCl, pH 7.8, 60 mM KCl, 1 mM DTT, 1 mM
PMSF, 1g/ml aprotinin, 0.3g/ml leupeptin and 10% glycerol) and 30 µl
of Buﬀer C (50 mM KCl, 20 mM HEPES, pH 7.8, 0.2 mM EDTA and 20%
glycerol). After incubation on ice for 15 min, nuclear extracts were
clariﬁed by centrifugation at 13,000×g for 30 min at 4 °C. Protein
concentration was estimated using Bradford protein assay (Bio-Rad
Laboratories Inc., Madrid, Spain).
2.10. Urea-PAGE for detection of TRX1 redox state
The method used for the detection of TRX redox state was developed
by Bersani et al. [28] and Takahashi and Hirose [29] and modiﬁed in
Du et al. [30]. Brieﬂy, to prepare mobility standards, cell lysates were
denatured and unfolded with urea and fully reduced with DTT.
Solutions with diﬀerent molar ratios of iodoacetic acid (IAA, Sigma-
Aldrich) and iodoacetamide (IAM, Sigma-Aldrich) were incubated with
the reduced proteins containing “n” cysteines, leading to “n+1”
possible labelled protein isoforms with introduced number of acidic
carboxymethyl thiol adducts (-SA-) and neutral amidomethyl thiol
adducts (-SM). During Urea-PAGE, the ionized -SA- adducts resulted
in faster protein migration toward the anode. Therefore, the “n+1”
isoforms were separated and used as a mobility standard for represent-
ing the number of -SA-. To determine the redox state of TRX1 in vivo,
cells were harvested by trypsinization and washed in ice-cold PBS to
remove secreted oxidized Trx1. Pelleted cells were immediately dis-
solved in TEU buﬀer (50 mM Tris– HCl, pH 8.2, 1 mM EDTA, 8 M Urea)
containing 30 mM IAA. Samples were incubated at 37 °C for 30 min,
centrifuged at 13,000×g for 10 min and transferred to fresh tubes. To
wash away excess IAA, proteins were precipitated with ice-cold
acetone-HCl and centrifuged at 13,000×g for 10 min, supernatants
were removed. Washing procedure was repeated two more times. The
ﬁnal pellet was dissolved in 100 µl TEU buﬀer with 3.5 mM DTT,
incubated for 30 min at 37 °C and subsequently alkylated with 10 mM
IAM for 15 min at 37 °C and centrifuged. Then protein concentration
was determined by Bradford protein assay and equal amounts of protein
were loaded into Urea-PAGE and electrotransfered to PVDF mem-
branes. Membranes were probed with Trx1 primary antibody (IMCO
Ltd. Stockholm, Sweden) and visualized by binding of horseradish
peroxidase conjugated anti-rabbit (Santa Cruz Biotechnology). Immu-
noreactivity was detected by using enhanced Immobilon Western
Substrates ECL (Millipore).
2.11. Quantitative real-time PCR
Total RNA was isolated by using Tri Reagent (Sigma-Aldrich),
according to manufacturer's instructions. Two micrograms of mRNA
were used to synthesize cDNA with High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA). Each sample
was analyzed in triplicate. The primers used in this assay were: Trx1 (5′-
GATCAAGCCTTTCTTTCATTCCC-CCCACCTTTTGTCCCTTCTTAA-3′), Tr
xR1 (5′-GGTCCAACCTTGAAGGCTTA-CATATTGGGCTGCCTCCTTA-3′)
TXNIP (5′- CTTACTGATCTATGTTAGGCGTTC-GGATGTTCAGATCT
ACCCAACT-3′) and β-Actin (5′-ATCAAGATCATTGCTCCTCCT-CATAGT
CCGCCTAGAAGCA-3′). β-Actin was employed as internal control.
Relative quantiﬁcation values are expressed as 2 (–delta CT).
2.12. Enzymatic activity
For the DTNB (5,5′-dithio-bis(2-nitrobenzoic acid)) endpoint assay
the thioredoxin reactions were coupled with insulin as protein substrate
according to method previously described [31]. Brieﬂy, 20 µg of
proteins were incubated with 85 mM HEPES pH 7.6, 3 mM EDTA,
0.3 mM insulin and 660 µM NADPH and with or without 50 nM TRXR.
After 30 min at 37 °C, a solution of 1 mM DTNB in 6 M guanidine-HCl
was added to stop the reaction and label and determine thiols.
Absorbance of samples was measured at 412 nm and the thiols
concentration was calculated using the extinction coeﬃcient of TNB
(13,600 M−1 cm−1).
2.13. Statistical analysis
Results shown represent the mean± standard error of the mean
(SEM) of at least three samples per group. Normality was assessed using
Kolmogorov-Smirnov test and then diﬀerences among means were
calculated using one-way ANOVA, followed by a Student-Newman-
Keuls (SNK) t-test. Values were considered statistically signiﬁcant when
p<0.05.
3. Results
3.1. Melatonin and silibinin inhibit cell growth while curcumin and
resveratrol induce apoptosis in prostate cancer cells
The eﬀects of four bioactive compounds (melatonin, silibinin,
curcumin and resveratrol) on the viability and proliferation of prostate
cancer cells were evaluated using MTT assay (Fig. 1A). After 48 h
treatment, the growth of androgen-sensitive LNCaP cells was signiﬁ-
cantly inhibited by melatonin 500 µM and 1 mM and silibinin 50 µM,
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while no signiﬁcant eﬀect was found in androgen-insensitive PC-3 cells
(Fig. 1A). Curcumin and resveratrol inhibited the viability of both cell
lines at concentrations over 10 and 20 µM, respectively. MTT assay
cannot discriminate cell growth inhibition from cell death. Thus,
annexinV staining in combination with ﬂow cytometry quantiﬁcation
of stained cells was performed after culturing LNCaP and PC-3 cells
Fig. 1. Eﬀect of bioactive compounds on viability in prostate cancer cells. (A) Androgen-sensitive LNCaP and androgen-insensitive PC-3 were exposed to melatonin, silibinin, curcumin or
resveratrol and MTT assay was performed after 48 incubation. Data are shown as mean±SEM. of six independent samples. Experiments were repeated at least three times. * p< 0.05; **
p<0.01; *** p< 0.001 versus CON. (B) Apoptosis was evaluated in LNCaP and PC-3 after 48 h incubation with IC50 of the compounds (1 mM melatonin, 50 µM silibinin, 25 µM
curcumin and 50 µM resveratrol), using Annexin V-FITC assay by ﬂow cytometry. (C) LNCaP cells were cultured with or without 1 mM melatonin, 50 µM silibinin, 25 µM curcumin or
50 µM resveratrol for 48 h. BCL-2 and BAX protein levels were assessed by western blot. GAPDH and β-Actin were employed as loading control. (D) Changes in cell morphology were
examined under a phase contrast microscope with a 200× magniﬁcation and photographed (scale bar, 25 µm).
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with melatonin (1 mM), silibinin (50 µM), curcumin (25 µM) or resver-
atrol (50 µM) (Fig. 1B). Only incubation with curcumin and resveratrol
induced a signiﬁcant increase in apoptotic cells in both cell types. To
conﬁrm this, the levels of anti-apoptotic protein BCL2 and pro-
apoptotic protein BAX were assessed by western blot. In LNCaP cells,
a clear decrease in BCL2 and an increase in BAX protein levels were
found after incubation with curcumin or resveratrol. On the contrary,
an increased in BCL2 was observed after melatonin incubation while no
signiﬁcant diﬀerences were observed in cells treated with silibinin in
BCL2/BAX ratio (Fig. 1C). Fig. 1D shows the morphology of LNCaP and
PC-3 cells after incubation for 48 h with all compounds. The character-
istic morphological features of apoptotic cells such as cell shrinkage,
rounded shape and partial detachment were all observed after curcu-
min incubation in both cell types. Similarly, PC-3 cells undergoing
resveratrol incubation showed morphological signs of apoptosis but
those were preceded by cytoplasmic vacuolization. Signiﬁcant changes
in the morphology, including long processes (neurites) and rounded
nuclei, typical features of neuroendocrine diﬀerentiation, were ob-
served in cells cultured with melatonin and silibinin as previously
reported [32].
To determine whether the decrease in cell viability was due to an
arrest of the cell cycle, LNCaP and PC-3 cells were treated with all
compounds for 48 h and cell cycle distribution was analyzed by ﬂow
cytometry (Fig. 2A). Melatonin and silibinin caused a signiﬁcant arrest
in G0/G1 in LNCaP cells (Fig. 2B), whereas no signiﬁcant diﬀerences
were found in androgen-insensitive PC-3 after incubation with these
agents. On the other hand, curcumin caused a G2 arrest in both cell
types besides increasing apoptosis (Fig. 2C). Interestingly, resveratrol
only promoted a signiﬁcant arrest in G1/S phase in androgen-insensi-
tive PC-3 cells. All together these results show that melatonin and
silibinin act as cytostatic agents but only in androgen-dependent cells
while curcumin and resveratrol display potent pro-apoptotic eﬀects in
both cell lines.
3.2. Curcumin increases oxidative stress in prostate cancer cells
The four bioactive compounds employed in this study have been
found to exert antioxidant properties in vitro [22,23,25,33], but their
eﬀects on growth inhibition in some tumor cell lines have been
sometimes related to ROS production [34,35]. We aim to investigate
whether an increase or a decrease in ROS levels occurred in PCa cells
after treatment with these compounds and if that eﬀect was an early
triggering event or a consequence of the apoptosis pathway. For this
purpose, cells were incubated for 30 min with the four compounds.
After incubation, cells were then stained with DHE and MitoSOX red
probes to evaluate the production of cytosolic or mitochondrial O2•-,
respectively (Fig. 3). As shown, only curcumin induced a signiﬁcant
increase in MitoSOX staining, being the ﬂuorescent intensity more than
ten times higher than in control cells. Not only did not melatonin,
silibinin and resveratrol increased but they rather decreased MitoSOX
ﬂuorescence, when compared to controls (Figs. 3A, B). Again, after DHE
staining, only curcumin-incubated cells showed a clear increase in
Fig. 2. Impact of bioactive compounds on cell cycle distribution in prostate cancer cells. (A) LNCaP and PC-3 cells were incubated with 1 mM melatonin, 50 µM silibinin, 25 µM curcumin
or 50 µM resveratrol for 24 h and cell cycle was analyzed by ﬂow cytometry. Data shown in the graphs is representative of three independent experiments. Bars represents the percentage
of cells in each phase of cell cycle for LNCaP (B) and PC-3 (C) after 24 h incubation with compounds. G0/G1 phase; S phase; G2/M phase.
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ﬂuorescence.
Since MitoSOX and DHE ﬂuorescence are indicatives of intracellular
O2•-, protein levels of SOD2/MnSOD, SOD1/CuZnSOD and catalase
were analyzed by Western blotting. No signiﬁcant diﬀerences were
found in SOD2 levels after any of the treatments (data not shown).
However, CuZnSOD protein levels were increased after melatonin
treatment in androgen-dependent LNCaP cells. Likewise, curcumin
and resveratrol increased CuZnSOD protein levels in both cell types
(Figs. 3E, F). Using CuZnSOD/Catalase ratio as a measurement of redox
balance, it was signiﬁcantly increased after curcumin treatment in
androgen-sensitive and insensitive cells, while resveratrol only showed
an eﬀect in PC-3 cells (Fig. 3G-H).
Given the imbalance in CuZnSOD/catalase observed in PC-3 cells
after incubation with both, curcumin and resveratrol, the levels of H2O2
were further analyzed to assay whether these compounds could also
alter intracellular ROS in a long-time fashion (Fig. 3I). Consequent with
that, a signiﬁcant increase in H2O2 released into cell culture media was
found after curcumin and resveratrol incubation. Altered CuZnSOD/
Catalase ratio and H2O2 levels prompted us to next measure ROS
production with DCFH2-DA (a general oxidative stress indicator) after a
longer exposure time to the stilbene. As shown in Fig. 3J, resveratrol, at
concentrations≥ IC50 signiﬁcantly increased ROS levels in PC-3 cells at
all times of incubation. These results suggest that both polyphenols
increase O2•- at shorter and H2O2 at longer exposure times thus
promoting oxidative stress in PC-3 cells.
3.3. NAC prevents curcumin-induced apoptosis
Since an early increase in ROS levels combined with a decrease in
catalase likely explains the mechanism of action of curcumin in LNCaP
and PC-3 cells, we tried to evaluate whether curcumin eﬀect on cell
viability could be prevented by incubation with N-acetyl-cysteine
(NAC), a precursor of glutathione (GSH). LNCaP (Fig. 4A) and PC-3
cells (Fig. 4B) were pre-treated with 20 mM NAC for 3 h and then
exposed to increasing concentrations of curcumin (25, 50, and 100 µM).
The eﬀect of curcumin on cell viability was greatly inhibited by pre-
incubation with NAC in both cell lines (Fig. 4A, B). In addition, pre-
incubation with NAC decreased nearly 90% the number of apoptotic
cells in the group treated with 100 µM curcumin (Fig. 4C), supporting
that the toxicity mediated by this compound might involve changes in
redox state in prostate cancer cells.
Comparably, resveratrol changed antioxidant enzymes levels and
induced an increase in H2O2 in PC-3 cells; therefore, the eﬀect of co-
incubation of NAC with the stilbene was also studied. A much less
signiﬁcant reduction on cell toxicity was observed when cells were pre-
incubated with NAC (Fig. 4D, E) suggesting that curcumin and
resveratrol induced apoptosis in prostate cancer cells following diﬀer-
ent mechanisms.
3.4. Inhibition of ASK1 activity prevents curcumin induced apoptosis
Melatonin and silibinin induce diﬀerentiation in prostate cells while
curcumin and resveratrol are able to induced apoptosis. For this reason,
the role of ASK1 in the biological activity of the four bioactive
compounds was evaluated. The phosphorylation of ASK1 at Ser-967
has been related to diﬀerentiation in other cell types [36] whereas
phosphorylation of ASK1 at Thr-845 has been associated with apoptosis
induction [37]. The level of endogenous ASK1 and phosphorylated
forms, P-ASK1Thr845 or P-ASK1Ser 967 were studied in prostate cancer
cells. Endogenous protein levels were too low to be detected by western
blot in LNCaP and PC-3 cells (data not shown) so both cell lines were
transfected with hASK1-HA-pcDNA3 and then immunoprecipitation
was carried out. No signiﬁcant signal for P-ASK1Thr-845 was detected
and only a slight increase in P-ASK1Ser 967 was observed in LNCaP cells
(data not shown).
In order to evaluate indirectly the participation of ASK1 in prostate
cancer survival, LNCaP and PC-3 cells were transfected with hASK1-HA-
pcDNA3 or the kinase mutant hASK1-KM-HApcDNA3 and cell viability
was assessed after treatment with curcumin and resveratrol by MTT
assay (Fig. 5A, B).
As expected (see above), curcumin and resveratrol reduced the
viability of both androgen-dependent and independent cells.
Overexpression of native ASK1 enhanced toxicity induced by both
polyphenols in LNCaP cells. In the case of the androgen independent
PC-3 cells, ASK1 overexpression only enhanced the toxicity caused by
curcumin (Fig. 5A, B). Overexpression of a mutant KM-ASK1 isoform
partially protected PC-3 cells from curcumin-caused toxicity (Fig. 5A)
while it had no eﬀect when cells were incubated with resveratrol. These
results suggested that ASK1 could play a role in curcumin but not in
resveratrol-induced toxicity. Thus, to further investigate the role of this
kinase in curcumin-mediated apoptosis, Annexin V-PI assay was
performed in PC-3 cells. However, in this case no signiﬁcant diﬀerences
were found between cells transfected with either, native or KM-ASK1
mutant (Fig. 5C).
3.5. TRX1 oxidation mediates curcumin and resveratrol-induced apoptosis
Since TRX1 is the major redox regulator of ASK1, we evaluated
the eﬀect of melatonin, silibinin, curcumin and resveratrol on TRX1
protein levels, subcellular location and redox state. Total protein
levels of TRX1 in LNCaP and PC-3 are shown in Fig. 6A and 6B,
respectively. Melatonin, silibinin and curcumin induced an increase
in TRX1 in both cell lines, while resveratrol displayed diﬀerent
eﬀects in androgen-sensitive and insensitive cells. Therefore, incuba-
tion with the stilbene caused an increase in TRX1 protein levels in
LNCaP but a signiﬁcant decrease in PC-3 cells (Fig. 6A and B).
Because TRX1 translocates into the nucleus under oxidative stress,
we analyzed its subcellular location after 48 h incubation with the
four compounds. Following incubation with melatonin and silibinin,
no signiﬁcant diﬀerences were found in TRX1 location in LNCaP
(Fig. 6C), although both clearly decreased nuclear TRX1 levels in the
androgen-independent cells (Fig. 6D). Curcumin signiﬁcantly in-
duced nuclear TRX1 translocation in both cell types while resveratrol
promoted an increase in its nuclear localization in LNCaP, but
dramatically decreased protein levels in both compartments in PC-
3 cells, consistent with the results mentioned above (Fig. 6B).
TRX1 activity is regulated by its redox state. Accordingly, the
oxidative state of TRX1 was evaluated by using a modiﬁed redox
western blot technique as previously described [30,38]. As shown in
Fig. 6E and F, TRX1 is not fully reduced in untreated LNCaP and PC-3
cells. Melatonin and silibinin did not change the basal redox state in
LNCaP and these compounds even caused a further TRX1 reduction in
Fig. 3. Eﬀect of bioactive compounds on ROS production and on antioxidant protein levels in prostate cancer cells. LNCaP and PC-3 cells were incubated with melatonin (250, 500,
1000 µM), silibinin (25, 50, 100 µM), curcumin (10, 25, 50 µM) or resveratrol (25, 50, 100 µM) for 30 min and stained with MitoSOX red (A, B) or DHE (C, D) for 30 min. Representative
histogram of MitoSOX ﬂuorescence shift after curcumin incubation in shown in the top corner of ﬁgures A and B. ROS levels were measured by ﬂow cytometry and are presented as the
percentage fold change relative to control cells. LNCaP (E) and PC-3 (F) were cultured with 1 mMmelatonin, 50 µM silibinin, 25 µM curcumin or 50 µM resveratrol for 48 h and CuZnSOD
and catalase protein levels were assessed by western blot. β-Actin was employed as loading control. Experiment was repeated at least 3 times and a representative experiment is shown.
CuZnSOD/catalase protein ratio was calculated in LNCaP (G) and PC-3 (H). (I) Eﬀect of bioactive compounds on H2O2 release in prostate cancer cells. Cells were cultured in complete
medium at a density of 75×105 cells/ml and incubated with 1 mM melatonin, 50 µM silibinin, 25 µM curcumin or 50 µM resveratrol for 24 h. An electro-oxidation method was used for
H2O2 determination. (J) PC-3 cells were exposed to resveratrol (25, 50, 100 µM) and ROS production was measured using DCFH2-DA after 3,6 or 24 h incubation. Data are shown as
mean± S.E.M of three independent samples. *p< 0.05; **p< 0.01; ***p< 0.001 versus CON. Experiment was repeated 3 times and a representative experiment is shown.
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PC-3 cells. On the other hand, treatment with curcumin increased TRX1
oxidation in both cells lines. Resveratrol showed a diﬀerent eﬀect and
led to a clear oxidation of TRX1 in LNCaP cells while in androgen-
independent PC-3 cells, although there is an increment of oxidation, we
observed a strong decrease in total TRX1 protein levels once more.
3.6. Resveratrol decreases TRX1 by increasing TXNIP mRNA levels in PC-3
cells
In order to conﬁrm whether curcumin and resveratrol treatment
modiﬁed TRX1 and TRXR1 activities or their mRNA levels, they were
Fig. 4. Inﬂuence of NAC on curcumin and resveratrol-induced toxicity. LNCaP (A) and PC-3 cells (B) were incubated with curcumin (25, 50 and 100 μM) alone or prior 3 h incubation
with 20 mM NAC. Cell viability was measured by MTT assay after 24 h treatment. PC-3 cells were treated with curcumin alone (C) or after prior incubation with NAC (D) for 36 h.
Apoptosis was measured by ﬂow cytometry after staining with Annexin V/PI. LNCaP (E) and PC-3 cells (F) were treated with resveratrol (25, 50 and 100 µM). Cell viability was measured
with MTT assay after 24 h. *p< 0.05; **p<0.01; ***p<0.001 versus CON.
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analyzed after 48 h of exposure to the compounds in both cell lines.
Curcumin and resveratrol incubation increased TRX1 and TRXR1
transcription in LNCaP cells (Fig. 7A). On the other hand, curcumin
increased TRXR1mRNA levels but no signiﬁcant diﬀerences were found
in TRX1. Resveratrol dramatically decreased TRX1 transcription while
signiﬁcantly increased TRXR1 mRNA levels in PC-3 cells (Fig. 7B). No
diﬀerences were found in total TRX1 activity, at the concentrations
employed, neither in LNCaP nor in PC-3 cells treated with curcumin or
resveratrol (Fig. 8C). However, TRXR1 activity was signiﬁcantly
decreased after curcumin treatment in LNCaP cells (Fig. 7D).
In PC-3 cells TRX1 mRNA levels decreased after incubation with
resveratrol but this reduction did not seem to be signiﬁcant enough to
explain the substantial decrease in TRX1 protein levels found.
Although, this fact could be explained by a slow translational rate or
a rapid proteasomal degradation. To analyze whether TRX1 could be
released after resveratrol treatment in PC-3 cells, we evaluated the
protein levels in the cultured media. However, no signiﬁcant diﬀer-
ences were found (data not shown). Then, the potential role of TRX1
inhibitor, TXNIP, in the TRX1 reduction induced by resveratrol was
considered. A remarkable increase in TXNIP mRNA levels was found
after resveratrol incubation in both, LNCaP and PC-3 cells, while
curcumin showed no eﬀect on TXNIP transcription. (Fig. 7E). Interest-
ingly, melatonin and silibinin decreased the mRNA levels for the
inhibitor in both cell lines (data not shown).
All together, these data suggest that curcumin and resveratrol aﬀect
diﬀerently TRX1 but that in both, an increase in TRX1 oxidation is
associated with an increase in cell death (Fig. 8).
4. Discussion
Chemo-preventive properties of bioactive compounds and their
potential use in cancer treatment have been tested for years.
However, their speciﬁc targets, the limited knowledge of their mechan-
isms of action as well as their mechanistic diﬀerences have restricted
their utility. Here it is conﬁrmed that these four diﬀerent bioactive
compounds display cell type-dependent eﬀects resulting in diverse
outcomes in terms of cell redox modulation, pointing out the complex-
ity of their biological properties. While melatonin and silibinin show
antioxidant activity, curcumin and resveratrol induce cell death, with
diﬀerent eﬀects on the TRX system.
Previous studies had found that silibinin decreases both, intracel-
lular and secreted levels of PSA in LNCaP as well as promotes cell cycle
arrest without inducing apoptosis but rather causing neuroendocrine
diﬀerentiation of PCa cells [39]. Interestingly, similar results were
found with melatonin, where it was shown that the indole increases
neuroendocrine markers and that this neuroendocrine-like phenotype
increases cells sensitivity to apoptosis induced by cytokines [32,40]. On
the other hand, several reports demonstrate that curcumin and
resveratrol have pro-apoptotic eﬀects in prostate cancer both in vitro
and in vivo [19,41–43]. The pro-apoptotic and anti-proliferative proper-
Fig. 5. Eﬀect of curcumin and resveratrol on ASK1-overexpressed cells viability. LNCaP and PC-3 cells were transiently transfected with vector pcDNA3.1 (MOCK), wild-type ASK1
(ASK1) or kinase inactive mutant (KM-ASK1). Cells were set overnight and then treated with 25 µM curcumin (A) or 50 µM resveratrol (B). Cell viability was studied using MTT assay after
24 treatment. Data are shown as mean± S.E.M. of 6 independent samples. *p< 0.05; **p< 0.01; ***p< 0.001 versus CON. PC-3 cells (C) transiently transfected with vector, ASK1 or
KM-ASK1 were incubated with or without curcumin (25 µM) for 24 h. Apoptosis was evaluated after staining with Annexin V/PI by ﬂow cytometry.
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Fig. 6. Inﬂuence of bioactive compounds on TRX1 levels, subcellular localization and redox state. LNCaP (A, C) and PC-3 (B, D) cells were treated with 1 mM melatonin, 50 µM silibinin,
25 µM curcumin or 50 µM resveratrol for 48 h and TRX1 protein levels were evaluated by western blot. HDAC2 and β-Actin were employed as loading controls. Redox state of TRX1 in
LNCaP (E) and PC-3 (F) was analyzed after 48 h of treatment. Experiments were repeated at least 3 times and data of a representative experiment is shown.
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ties of these compounds have been linked to their eﬀects on protein
kinases, transcription factors, cell cycle proteins, cell adhesion mole-
cules, pro and anti-apoptotic proteins, inﬂammatory pathways and
growth signaling pathways [44] but its role as antioxidants or pro-
oxidants was also postulated.
Here it is conﬁrmed that melatonin and silibinin exhibited an
inhibitory growth eﬀect on androgen-dependent LNCaP cells, without
inducing cell death. LNCaP cells are by far the most commonly used
androgen-dependent PCa cell model. As a result, the speciﬁcity of the
indole and the ﬂavonoid on LNCaP cells might indicate an androgenic
pathway-related target. This is not the case for curcumin and resver-
atrol, which exhibit pro-apoptotic eﬀects in both cell lines, being the
apoptosis promotion more remarkable in the more aggressive andro-
gen-independent PC-3 cells.
Fig. 7. Eﬀect of curcumin and resveratrol on TRX1, TRXR1 and TXNIP mRNA levels and enzymatic activities in prostate cancer cells. LNCaP and PC-3 cells were incubated with 25 µM
curcumin or 50 µM resveratrol for 48 h. Trx1 and TrxR1mRNA levels in LNCaP (A) and PC-3 (B) were analyzed by RT-qPCR. TRX (C) and TRXR (D) enzymatic activities were analyzed in
LNCaP and PC-3 cells after 25 µM curcumin or 50 µM resveratrol for 48 h. Txnip mRNA levels (E) were analyzed by RT-qPCR. Graphs represent the mean± SEM obtained from three
independent experiments performed in triplicates. *p<0.05; #p<0.01; ***p< 0.001 versus CON.
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Curcumin inhibits cell proliferation at multiple levels within the
transcriptional network. This compound is well known for its antiox-
idant properties acting as a free radical scavenger by inhibiting lipid
peroxidation and oxidative DNA damage [45,46]. Additionally, it has
been proposed that curcumin-induced apoptosis might be triggered by
ROS production and/or oxidative stress in some tumor cells [47]. Here
we demonstrated that curcumin increases O2•- production after short-
term incubation and this pro-apoptotic eﬀect is remarkably prevented
by pre-incubation with NAC, implying that ROS are key players in this
cell death induction. Resveratrol also increases ROS levels but requires
a much longer incubation, suggesting that the oxidative stress caused
by this stilbene is rather a collateral consequence of the apoptotic
process. On the contrary, melatonin and silibinin did not trigger any
sign of oxidative stress, consistent with their lack of proapoptotic
eﬀects. Furthermore, both compounds reduced mitochondrial super-
oxide levels after short-time incubation, whereas no diﬀerences in
cytoplasmic ROS or in H2O2 production were found, compared to
control cells, suggesting that both compounds have a local mitochon-
drial action. The antioxidant potential of silibinin [48] and melato-
nin [49] has been described in several cellular and animal models. The
role of the indole as a direct antioxidant and as a major regulator of the
key antioxidant enzymes have being already reported [24,48] although
concentrations required for direct ROS scavenging are relatively high,
in accordance with the results shown here.
Here, for the ﬁrst time, the eﬀect of these compounds on TRX1/
TRX1 R in PCa cells was evaluated. This antioxidant system does not
simply act as a ROS scavenger but instead as an oxidative stress
regulator through protein-protein interaction. Recently, TRX1 has been
proposed as a subcellular biomarker of redox imbalance in prostate
cancer [26] and high TRX1 expression has been associated with drug
resistance in tumor cells [50,51]. TRX1 quickly translocates into the
nucleus in response to oxidative stress, NF-κB activation, UVB irradia-
tion or tumor necrosis factor α treatment [52]. In this regard, the four
compounds employed aﬀected diﬀerently the subcellular localization
and redox state of TRX1. Again, a dichotomy was clearly observed,
while melatonin and silibinin decreased nuclear TRX1, curcumin and
resveratrol increased its nuclear translocation in PC-3 cells. Despite the
fact that nuclear translocation might initiate pro-survival signals, this
signaling is likely to be useless under a situation of persistent redox
imbalance, which would ultimately aﬀect TRX1 oxidation and protein
activity.
Furthermore, curcumin promotes TRX1 nuclear localization and
oxidation in both cell lines. Fang et al. reported that curcumin is able to
irreversibly modify and inactivate TRXR1 [53], resulting in TRX1
oxidation and inactivation of NADPH oxidase activity, leading to an
increase in ROS production. In agreement with this, our results show
oxidation of TRX1 induced by both, curcumin and resveratrol. None-
theless, these compounds increased not only TRX1 but also TRXR1
mRNA levels in LNCaP, which appears to be a clear compensating
eﬀect. Reduced, but not oxidized TRX1 is able to bind and inhibit ASK1
activity, whereas ASK1 activation by TRX1 oxidation results in
apoptosis [9]. As shown in this work, overexpression of dominant-
negative ASK1-KM inhibits curcumin-induced cell death in PC-3 cells.
Therefore, ROS production, subsequent TRX1 oxidation and ASK1
activation appear as the most plausible pathway to explain curcumin-
induced apoptosis in these cell lines. To our knowledge, this is the ﬁrst
report evaluating the eﬀects of resveratrol on TRX1 subcellular location
and redox state. Interestingly, this stilbene displays diﬀerent eﬀects on
androgen-sensitive and insensitive PCa cells, i.e. promoting TRX1
nuclear translocation and oxidation in LNCaP and decreasing dramati-
cally protein levels in PC-3 cells. The same ﬁndings have been reported
with ﬂavonoids such as quercetin or myricetin, which inhibit TRXR
promoting TRX1 oxidation [54]. The decrease in total protein content
found in resveratrol-treated PC-3 cells could be explained in terms of
the reduced transcription but other mechanisms such as proteasomal
degradation cannot be excluded.
TXNIP is the only known endogenous TRX1 inhibitor, which binds
to reduced TRX1 and forms disulﬁde bonds with cysteine residues at its
catalytic center, thereby suppressing its activity [55,56]. Consequent
with the eﬀects on TRX1, resveratrol incubation led to an increase in
mRNA levels of TXNIP in both cell types, which might be important for
its antitumor activity. TXNIP expression is dramatically altered in
several tumors [57–59] and has emerged as an important element in
the pathogenesis of many cancers and metabolic diseases. TRX1
inhibition by TXNIP may aﬀect cell signaling by reducing its ability
to interact with other key partners. As a result, TXNIP overexpression
increases ROS levels in other cell types [60]. Moreover, Yamaguchi
et al. have demonstrated that TXNIP overexpression can induce G1 cell
cycle arrest [61]. In agreement with those studies, resveratrol-induced
cell cycle arrest and TRX1 oxidation shown here could be a conse-
quence of its eﬀects on TXNIP transcription.
Natural bioactive compounds such as the ones employed in this
study, have gained considerable attention not only as chemopreventive
agents but also as sensitizers of anticancer drugs [16,62]. However,
they usually exert poor solubility, weak bioavailability and a high
metabolization, which have been a barrier for the development of
therapeutic applications [63,64]. In this context, an increasing number
of studies aim to design novel formulations to overcome these
problems. Current attempts have focused in the development of new
delivery systems and more bioavailable analogues in order to increase
bioavailability while preserving their biological activity [65,66]. All
these new approaches allow natural compounds to play a signiﬁcant
role in the development of new therapies against several malignancies
once more.
5. Conclusion
To summarize, the present study provides new ﬁndings to explain
why redox-altering bioactive compounds exert diﬀerent properties in
tumor cells and consequently to understand the role of redox home-
ostasis on tumor progression. This will help to develop new anti-tumor
drugs based on redox modulation, which is a promising approach to
ﬁght the disease. Here we demonstrated that the redox protein TRX1
might play a key role in PCa survival after treatment with pro/anti-
apoptotic compounds. Curcumin causes an increase in ROS and an
oxidation of TRX1 while resveratrol dramatically diminishes its levels
while increase the transcription of TRX1 inhibitor, TXNIP and promote
a further increase in ROS levels (Fig. 8). Both substances lead to
apoptosis in androgen sensitive and insensitive prostate cells by
promoting oxidative stress rather than through their antioxidant
properties frequently exhibited in vitro. On the contrary, cytostatic
Fig. 8. Schematic illustration of curcumin and resveratrol regulation of thioredoxin
signaling in prostate cancer cells.
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agents as melatonin and silibinin favor diﬀerentiation instead of
apoptosis in prostate cancer cells by increasing their antioxidant
capacity via the reduction of TRX1 oxidation and its nuclear transloca-
tion.
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